Shares of Amgen surge on advancements in weight loss drug development, while those of Novo Nordisk and Eli Lilly decline

Amgen soars on weight loss drug progress, Novo Nordisk, Eli Lilly slide

Welcome to Extreme Investor Network, where we offer unique insights and analysis on the latest trends and developments in the business news world. Today, we’re diving into the exciting updates from Amgen that have sent … Read more